The closing price of Akebia Therapeutics Inc. (NASDAQ: AKBA) was $1.49 for the day, down -1.32% from the previous closing price of $1.51. In other words, the price has decreased by -$0.0200 from its previous closing price. On the day, 3617784 shares were traded. AKBA stock price reached its highest trading level at $1.5600 during the session, while it also had its lowest trading level at $1.4800.
Ratios:
Our analysis of AKBA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.18.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 29 ’24 when Butler John P. sold 46,570 shares for $1.58 per share. The transaction valued at 73,581 led to the insider holds 2,044,580 shares of the business.
Dahan Michel sold 8,661 shares of AKBA for $13,684 on Feb 29 ’24. The SVP, Chief Operating Officer now owns 706,932 shares after completing the transaction at $1.58 per share. On Feb 29 ’24, another insider, Burke Steven Keith, who serves as the SVP, Chief Medical Officer of the company, sold 7,169 shares for $1.58 each. As a result, the insider received 11,327 and left with 695,840 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 309.87M and an Enterprise Value of 315.07M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.60. Its current Enterprise Value per Revenue stands at 1.62 whereas that against EBITDA is -77.85.
Stock Price History:
Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.49. The 50-Day Moving Average of the stock is 1.6368, while the 200-Day Moving Average is calculated to be 1.2909.
Shares Statistics:
AKBA traded an average of 4.58M shares per day over the past three months and 13.9M shares per day over the past ten days. A total of 194.58M shares are outstanding, with a floating share count of 184.15M. Insiders hold about 12.05% of the company’s shares, while institutions hold 18.43% stake in the company. Shares short for AKBA as of Mar 15, 2024 were 10.13M with a Short Ratio of 2.21, compared to 8M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.84% and a Short% of Float of 4.89%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.05 and a low estimate of -$0.11, while EPS last year was -$0.14. The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.03 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.21 and -$0.37 for the fiscal current year, implying an average EPS of -$0.29. EPS for the following year is -$0.29, with 3 analysts recommending between $0.17 and -$0.58.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $56M to a low estimate of $40.1M. As of the current estimate, Akebia Therapeutics Inc.’s year-ago sales were $40.13M, an estimated increase of 15.50% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $49.51M, a decrease of -12.20% less than the figure of $15.50% in the same quarter last year. There is a high estimate of $54M for the next quarter, whereas the lowest estimate is $45.79M.
A total of 3 analysts have provided revenue estimates for AKBA’s current fiscal year. The highest revenue estimate was $191.06M, while the lowest revenue estimate was $188.1M, resulting in an average revenue estimate of $189.09M. In the same quarter a year ago, actual revenue was $194.62M, down -2.80% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $171.49M in the next fiscal year. The high estimate is $198.6M and the low estimate is $125.9M. The average revenue growth estimate for next year is down -9.30% from the average revenue estimate for this year.
